Skip to content

Trial Summary

The aim of this study is to compare the effects of Osimertinib alone versus SRS plus Osimertinib on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors.



ACTRN/NCT /ethics:


Scientific title:

A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Sponsor / Cooperative group:

Trans Tasman Radiation Oncology Group

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2019-08-15
Anticipated End Date2024-03-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Hein Le
Recruitment StatusRecruiting